EUVIMEDEUVIMED entdecken
Übersichtsarbeit

RNA Therapeutics for the Cardiovascular System

Victor J Dzau iD, Conrad P Hodgkinson

Circulation · 27.02.2024 · 149 (9) · 707-716

DOI: 10.1161/circulationaha.123.067373 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Circulation, erschienen am 27.02.2024. Verfasst von Victor J Dzau und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mandel Center for Hypertension and Atherosclerosis, and the Duke Cardiovascular Research Center, Duke University Medical Center, Durham, NC (V.J.D., …. Hauptthemen laut MEDLINE: Cardiovascular Diseases, MicroRNAs, Cardiovascular System. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 99 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA therapeutics hold significant promise in the treatment of cardiovascular diseases. RNAs are biologically diverse and functionally specific and can be used for gain- or loss-of-function purposes. The effectiveness of mRNA-based vaccines in the recent COVID-19 pandemic has undoubtedly proven the benefits of an RNA-based approach. RNA-based therapies are becoming more common as a treatment modality for cardiovascular disease. This is most evident in hypertension where several small interfering RNA–based drugs have proven to be effective in managing high blood pressure in several clinical trials. As befits a rapidly burgeoning field, there is significant interest in other classes of RNA. Revascularization of the infarcted heart through an mRNA drug is under clinical investigation. mRNA technology may provide the platform for the expression of paracrine factors for myocardial protection and regeneration. Emergent technologies on the basis of microRNAs and gene editing are tackling complex diseases in a novel fashion. RNA-based gene editing offers hope of permanent cures for monogenic cardiovascular diseases, and long-term control of complex diseases such as essential hypertension, as well. Likewise, microRNAs are proving effective in regenerating cardiac muscle. The aim of this review is to provide an overview of the current landscape of RNA-based therapies for the treatment of cardiovascular disease. The review describes the large number of RNA molecules that exist with a discussion of the clinical development of each RNA type. In addition, the review also presents a number of avenues for future development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesMicroRNAsCardiovascular SystemHumansPandemicsRNA, Small InterferingRNA, Messenger

Stichwörter der Autor:innen

RNARNA, messengerRNA, small interferinggene editinghypertensionimmunity, innatemicroRNAsmyocardial infarctionmyocardial revascularizationregeneration

Substanzen

MicroRNAsRNA, Small InterferingRNA, Messenger

Autor:innen und Institutionen

  • Mandel Center for Hypertension and Atherosclerosis, and the Duke Cardiovascular Research Center, Duke University Medical Center, Durham, NC (V.J.D., C.P.H.).
  • National Academy of Medicine, Washington, DC (V.J.D.).

ORCID-Profile: Victor J Dzau

Zitieren

APA

Dzau, V. J., & Hodgkinson, C. P. (2024). RNA Therapeutics for the Cardiovascular System. Circulation, 149(9), 707-716. https://doi.org/10.1161/circulationaha.123.067373

Vancouver

Dzau VJ, Hodgkinson CP. RNA Therapeutics for the Cardiovascular System. Circulation. 2024;149(9):707-716. doi:10.1161/circulationaha.123.067373

BibTeX
@article{Dzau2024,
  author = {Dzau, Victor J and Hodgkinson, Conrad P},
  title = {RNA Therapeutics for the Cardiovascular System},
  journal = {Circulation},
  year = {2024},
  volume = {149},
  number = {9},
  pages = {707--716},
  doi = {10.1161/circulationaha.123.067373}
}
Kostenlos starten →